Rein Therapeutics (RNTX) Capital Expenditures (2017 - 2021)

Rein Therapeutics (RNTX) posted quarterly Capital Expenditures of $5000.0 for Q3 2021, down 92.54% quarter-over-quarter from $67000.0 in Q2 2021.

Rein Therapeutics (RNTX) Capital Expenditures (2017 - 2021) Analysis & Trends

Rein Therapeutics (RNTX) has reported Capital Expenditures for 4 consecutive years, with $5000.0 the latest figure, recorded in Q3 2021.

In Q3 2021, Capital Expenditures changed N/A year-over-year to $5000.0; the TTM figure through Dec 2021 stood at $157000.0 (up 685.0% YoY), while the FY2021 annual figure was $157000.0, up 3040.0% from the prior year.
Capital Expenditures eased to $5000.0 in Q3 2021 per RNTX's latest filing, from $67000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $2.3 million in Q3 2018 and bottomed at $4000.0 in Q2 2019.
Historically, Capital Expenditures has averaged $221266.7 across 4 years, with a median of $38000.0 in 2017.
Annual changes were most pronounced in 2018 — Capital Expenditures soared 8337.04% — and 2019, when it slumped 99.78%.
Rein Therapeutics' Capital Expenditures stood at $68000.0 in 2017, then surged by 455.88% to $378000.0 in 2018, then sank by 96.03% to $15000.0 in 2019, then slumped by 66.67% to $5000.0 in 2021.
Business Quant data shows RNTX's Capital Expenditures at $5000.0 in Q3 2021, $67000.0 in Q2 2021, and $85000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Rein Therapeutics	55.49 Mn	55.49 Mn	-	-

Download Data